Joseph Pearlberg
Director/Board Member chez NUVALENT, INC.
Profil
Joseph Pearlberg is an Independent Director at Nuvalent, Inc. He is also a Director at Neomorph, Inc. and an Associate at The Broad Institute, Inc. In addition, he is a Vice President at Deerfield Management Co. LP (Private Equity) since 2017.
Previously, he worked as a Medical Director at Sanofi SA and as a Vice President-Clinical Development at Infinity Pharmaceuticals, Inc. from 2014 to 2017.
Dr. Pearlberg holds a doctorate degree from Harvard University, an undergraduate degree from the University of Pennsylvania, and another doctorate degree from The University of California, San Francisco.
Postes actifs de Joseph Pearlberg
| Sociétés | Poste | Début |
|---|---|---|
| NUVALENT, INC. | Director/Board Member | 01/01/2021 |
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Neomorph, Inc.
 Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Neomorph, Inc. is an American venture-backed biotechnology company that focuses on discovering innovative new medicines against 'undruggable' targets to solve critical problems in human health. The company is headquartered in an undisclosed location and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who are committed to advancing the science and technology of molecular glue drug discovery. The company's patient-first, science-driven approach is complemented by its dedication to a supportive and collaborative work environment. Neomorph was founded by Eric Fischer, Philip Chamberlain, Scott A. Armstrong, and Benjamin Ebert, with Philip Chamberlain serving as the CEO since incorporation. | Director/Board Member | - |
Deerfield Management Co. LP (Private Equity)
 Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York. | Private Equity Investor | 01/07/2017 |
Anciens postes connus de Joseph Pearlberg
| Sociétés | Poste | Fin |
|---|---|---|
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/07/2017 |
| Sanofi SA | Chief Tech/Sci/R&D Officer | - |
Formation de Joseph Pearlberg
| Harvard University | Doctorate Degree |
| University of Pennsylvania | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| NUVALENT, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
| Sanofi SA | Health Technology |
Deerfield Management Co. LP (Private Equity)
Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York. | Finance |
Neomorph, Inc.
Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Neomorph, Inc. is an American venture-backed biotechnology company that focuses on discovering innovative new medicines against 'undruggable' targets to solve critical problems in human health. The company is headquartered in an undisclosed location and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who are committed to advancing the science and technology of molecular glue drug discovery. The company's patient-first, science-driven approach is complemented by its dedication to a supportive and collaborative work environment. Neomorph was founded by Eric Fischer, Philip Chamberlain, Scott A. Armstrong, and Benjamin Ebert, with Philip Chamberlain serving as the CEO since incorporation. | Health Technology |
